Ou Y - Search Results

1

Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.

Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J. Ou Y, et al. J Clin Pharmacol. 2017 May;57(5):663-677. doi: 10.1002/jcph.850. Epub 2016 Dec 7. J Clin Pharmacol. 2017. PMID: 27925676 Clinical Trial.

2

Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: a case study.

Ou YC, Lo A, Lee B, Liu P, Kimura K, Eary C, Hopkins A. Ou YC, et al. J Clin Pharmacol. 2013 Nov;53(11):1112-20. doi: 10.1002/jcph.157. Epub 2013 Aug 29. J Clin Pharmacol. 2013. PMID: 23913679

3

A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.

Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R, Badros A, Aggarwal S, Bruno R. Jonsson F, et al. Among authors: ou y. CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):711-9. doi: 10.1002/psp4.12044. Epub 2015 Nov 20. CPT Pharmacometrics Syst Pharmacol. 2015. PMID: 26904385 Free PMC article.

4

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. Berenson JR, et al. Among authors: ou y. Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12. Blood. 2016. PMID: 27207788 Free PMC article. Clinical Trial.

5

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.

Quach H, White D, Spencer A, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M. Quach H, et al. Among authors: ou y. Cancer Chemother Pharmacol. 2017 Jun;79(6):1067-1076. doi: 10.1007/s00280-017-3287-8. Epub 2017 Apr 19. Cancer Chemother Pharmacol. 2017. PMID: 28424963 Free PMC article. Clinical Trial.

6

Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM. Ou Y, et al. Br J Clin Pharmacol. 2019 Mar;85(3):530-539. doi: 10.1111/bcp.13817. Epub 2018 Dec 25. Br J Clin Pharmacol. 2019. PMID: 30428505 Free PMC article. Clinical Trial.

7

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study.

Brown J, Plummer R, Bauer TM, Anthony S, Sarantopoulos J, De Vos F, White M, Schupp M, Ou Y, Vaishampayan U. Brown J, et al. Among authors: ou y. Exp Hematol Oncol. 2017 Oct 3;6:27. doi: 10.1186/s40164-017-0086-1. eCollection 2017. Exp Hematol Oncol. 2017. PMID: 29026685 Free PMC article.

8

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.

Ou YC, Liu L, Tariq B, Wang K, Jindal A, Tang Z, Gao Y, Sahasranaman S. Ou YC, et al. Clin Transl Sci. 2021 Mar;14(2):764-772. doi: 10.1111/cts.12948. Epub 2021 Jan 25. Clin Transl Sci. 2021. PMID: 33306268 Free PMC article.

9

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.

Ou YC, Tang Z, Novotny W, Tawashi M, Li TK, Coleman HA, Sahasranaman S. Ou YC, et al. Br J Clin Pharmacol. 2021 Jul;87(7):2926-2936. doi: 10.1111/bcp.14707. Epub 2021 Jan 14. Br J Clin Pharmacol. 2021. PMID: 33336408 Free PMC article.

10

Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.

Tam CS, Ou YC, Trotman J, Opat S. Tam CS, et al. Expert Rev Clin Pharmacol. 2021 Nov;14(11):1329-1344. doi: 10.1080/17512433.2021.1978288. Epub 2021 Sep 20. Expert Rev Clin Pharmacol. 2021. PMID: 34491123 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,271 results

Search Page

Filters